Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05442190 · ClinicalTrials.gov registry record · Phase 2
Topical SGX302 for Mild-to-Moderate Psoriasis
A Phase 2 study, sponsored by Soligenix.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT05442190 is a Phase 2 study that has completed, run by Soligenix. The registered enrollment target is 15 participants.
The verdict
NCT05442190, a Phase 2 study, has completed, sponsored by Soligenix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
To evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.
Interventions
- DRUG Placebo
- DRUG Hypericin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2025-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05442190
The ClinicalTrials.gov registry entry for NCT05442190 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Soligenix, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05442190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05442190 about?
NCT05442190 is a clinical study titled "Topical SGX302 for Mild-to-Moderate Psoriasis". To evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.
What is the current status of trial NCT05442190?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2022-12-14. Estimated completion is 2025-11-17.
What interventions are being tested in trial NCT05442190?
The interventions under investigation include: Placebo (DRUG), Hypericin (DRUG).
Who is sponsoring clinical trial NCT05442190?
This trial is sponsored by Soligenix, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.